Literature DB >> 26174590

Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.

Zuzana Obertová1, Fraser Hodgson1, Joseph Scott-Jones2, Charis Brown1, Ross Lawrenson1.   

Abstract

PURPOSE: To examine prostate-specific antigen (PSA) screening patterns and outcomes in rural and urban men in New Zealand.
METHODS: Men aged 40+ years were identified from 18 rural and 13 urban general practices across the Midland Cancer Network region. Computerized practice records were cross-referenced with community laboratory data to ascertain the number and level of PSA tests undertaken in 2010 and 3 years prior. For men with an elevated PSA result in 2010, practice records were searched for information on specialist visits, and they were cross-referenced with histology reports regarding biopsy and prostate cancer diagnosis.
FINDINGS: The study population included 34,960 men aged 40+ years, of whom 48% were enrolled in rural practices. Men in rural practices were 43% less likely to be screened with a PSA test in 2010, but they were 53% more likely to have an elevated PSA result. The prostate cancer detection rate from all screened men was 6 per 1,000 for rural men compared with 3 per 1,000 for urban men. Rural men were more likely diagnosed with Gleason score 9 tumors and metastatic disease.
CONCLUSION: Significant differences were found in PSA screening patterns between rural and urban general practices. Due to lower screening rates, rural men were more likely to be diagnosed with prostate cancer when screened and also seemed to be diagnosed with more advanced disease compared with urban men. Despite ongoing discussions about the benefits and harms of PSA screening, PSA testing as such seems to be under-utilized in New Zealand rural practices.
© 2015 National Rural Health Association.

Entities:  

Keywords:  general practice; prostate cancer; residence; rural; screening

Mesh:

Substances:

Year:  2015        PMID: 26174590     DOI: 10.1111/jrh.12127

Source DB:  PubMed          Journal:  J Rural Health        ISSN: 0890-765X            Impact factor:   4.333


  6 in total

1.  Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia.

Authors:  Rasa Ruseckaite; Fanny Sampurno; Jeremy Millar; Mark Frydenberg; Sue Evans
Journal:  BMC Urol       Date:  2016-09-02       Impact factor: 2.264

2.  Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts.

Authors:  Nishi Karunasinghe; Stefan Ambs; Alice Wang; Wei Tang; Shuotun Zhu; Tiffany H Dorsey; Megan Goudie; Jonathan G Masters; Lynnette R Ferguson
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240

3.  Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions.

Authors:  Nishi Karunasinghe; Tsion Zewdu Minas; Bo-Ying Bao; Arier Lee; Alice Wang; Shuotun Zhu; Jonathan Masters; Megan Goudie; Shu-Pin Huang; Frank J Jenkins; Lynnette R Ferguson
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

4.  Urban-rural prostate cancer disparities in a regional state of Australia.

Authors:  Georgea R Foley; C Leigh Blizzard; Brian Stokes; Marketa Skala; Frank Redwig; Joanne L Dickinson; Liesel M FitzGerald
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

5.  Men's perceptions of prostate cancer diagnosis and care: insights from qualitative interviews in Victoria, Australia.

Authors:  Maggie Kirkman; Kate Young; Susan Evans; Jeremy Millar; Jane Fisher; Danielle Mazza; Rasa Ruseckaite
Journal:  BMC Cancer       Date:  2017-10-27       Impact factor: 4.430

6.  Attitudes of rural communities towards the use of technology for health purposes in New Zealand: a focus group study.

Authors:  Duncan R Babbage; Kirsten van Kessel; Agnes Terraschke; Juliet Drown; Hinemoa Elder
Journal:  BMJ Open       Date:  2020-06-01       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.